BioRestorative Therapies Inc (FRA:9OF)

Q2 2025 BioRestorative Therapies Inc Earnings Call Transcript

Aug 12, 2025 / 08:30 PM GMT

Release Date Price: €1.2 (-1.64%)

Transcript 10-Q8-K

Key Points

Positve

BioRestorative Therapies Inc (BRTX) reported a significant increase in revenue, up 240% from the previous year, primarily due to a contract manufacturing agreement on biocosmaceuticals.
The company ended the quarter in a strong financial position with $7.4 million in cash equivalents and marketable securities, and no outstanding debt.
The ongoing phase two trial for BRTX 100 shows promising results, with over 74% of subjects showing greater than 50% improvement in function and over 72% reporting greater than 50% reduction in pain.
No serious adverse events or dose-limiting toxicities were reported in the BRTX 100 trial, indicating a strong safety profile.
The company is in advanced discussions for potential licensing agreements for its ThermoStem metabolic disease programs, indicating potential future revenue streams.

Negative

Despite the revenue increase, BioRestorative Therapies Inc (BRTX) reported a net loss of $2.7 million for the quarter.
The company's loss from operations increased to $3.3 million compared to $2.5 million in the same period last year.
The revenue growth from biocosmaceuticals is still uncertain and considered 'lumpy,' making future projections challenging.
The company is heavily reliant on the success of its clinical trials and regulatory approvals, which carry inherent risks and uncertainties.
There is no specific guidance on future revenue expectations from the biocosmaceuticals segment, indicating potential volatility.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BRTX.OQ - BioRestorative Therapies Inc
Q2 2025 BioRestorative Therapies Inc Earnings Call
Aug 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the bio restorative therapy's 2nd quarter 2025 results and business update conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press 0 on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host Stephen Kilmer, Investor Relations. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Ali. Good afternoon, everyone

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.